In the BioHarmony Drug Report Database
Savella (milnacipran) is a small molecule pharmaceutical. Milnacipran was first approved as Savella on 2009-01-14. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. Savella’s patents are valid until 2029-09-19 (FDA).
Image (chem structure or protein)